Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    ARCHAIC -hydroxychloroquine, 2020
     
    NL8490
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
    9/6 inconclusive
      CCAP-1, 2020
       
      NCT04345289
      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
      -/- inconclusive
        Chen, 2020
         
        NCT04384380
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        21/12 inconclusive
          Duke university HCQ, 2020
           
          NCT04335552
          RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
          4/2 no results
            discontinued, found in Axfors et al. meta-analysis
            HAHPS, 2020
             
            NCT04329832
            RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
            42/43 inconclusive
            • inconclusive 7 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
            HYCOVID, 2020
             
            NCT04325893
            RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
            124/123 inconclusive
            • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
            NO COVID-19 (Lyngbakken), 2020
             
            NCT04316377
            RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
            27/26 inconclusive
              OAHU-COVID19, 2020
               
              NCT04345692
              RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
              10/6 inconclusive
                ORCHID, 2020
                 
                NCT04332991
                RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
                242/237 inconclusive
                • inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
                PROTECT B, 2020
                 
                NCT04338698
                RCThydroxychloroquineoseltamivirCOVID 19 hospitalizedNA
                -/- inconclusive
                  RECOVERY, 2020
                   
                  NCT04381936
                  RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                  1561/3155 safety concern
                  • inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                  • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
                  Sekhavati, 2020 RCThydroxychloroquinelopinavir/ritonavirCOVID 19 hospitalizedsome concern
                  56/55 inconclusive
                  • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Sekhavati, 2020 RCThydroxychloroquinehydroxychloroquineCOVID 19 hospitalizedsome concern
                  56/55 inconclusive
                  • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                  SOLIDARITY (WHO study) HCQ, 2020
                   
                  NCT04315948
                  RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                  947/906 inconclusive
                  • inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Tang, 2020
                   
                  ChiCTR2000029868
                  RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
                  75/75 safety concern
                  • statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
                  TEACH, 2020
                   
                  NCT04369742
                  RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
                  67/61 inconclusive
                  • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                  • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Arshad (HCQ), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                  1202/409 suggested
                  • suggested 66 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                  Belgian Collaborative Group on COVID-19, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                  4542/3533 suggested
                  • suggested 32 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
                  Geleris, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                  811/565 inconclusive
                    Magagnoli (HC), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                    97/158 safety concern
                    • safety concern with statistically significant 1.6-fold increase in deaths,deaths (time to event analysis only)
                    Novales, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                    123/43 suggested
                    • suggested 93 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
                    Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
                    38/46 inconclusive
                      Sbidian (HCQ alone), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                      623/3792 safety concern
                      • statistically significant 25 % increase in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                      Singh, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                      -/- inconclusive

                        COVID 19 all comers meta-analysis

                        ChiCTR2000030054-HCQ (Chen), 2020
                         
                        ChiCTR2000030054
                        RCThydroxychloroquinestandard of careCOVID 19 all comershigh
                        18/12 inconclusive
                          Gautret et al., 2020 NRahydroxychloroquinecontrolCOVID 19 all comersserious
                          20/16 suggested
                          • suggested 15.3-fold increase in PCR-negative conversion (PE) but with a low degree of certainty due to high risk of bias
                          a viral load reduction/disappearance is claimed but the numerous methological limits preclude any strong conclusion

                          COVID-19 mild to moderate meta-analysis

                          Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
                           
                          NCT04322123
                          RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                          221/227 safety concern
                          • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                          HC-nCoV (Shanghai), 2020
                           
                          NCT04261517
                          RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                          15/15 inconclusive
                            NCT04333654, 2020
                             
                            NCT04333654
                            RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
                            -/- inconclusive
                              Zhaowei Chen, 2020
                               
                              ChiCTR2000029559
                              RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
                              31/31 inconclusive
                                Zhaowei Chen, 2020
                                 
                                ChiCTR2000029559
                                RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
                                31/31 suggested
                                • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
                                • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
                                Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
                                20/20 inconclusive

                                  COVID-19 severe or critically meta-analysis

                                  HYDRA, 2020
                                   
                                  NCT04315896
                                  RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
                                  75/77 inconclusive
                                  • inconclusive 1 % decrease in deaths (PE)
                                  REMAP-CAP-HCQ, 2020
                                   
                                  NCT02735707
                                  RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
                                  61/81 inconclusive
                                  • inconclusive 4 % increase in deaths (PE)
                                  REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
                                  Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
                                  84/97 inconclusive
                                    Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
                                    48/520 suggested
                                    • suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

                                    COVID 19 outpatients meta-analysis

                                    BCN PEP-CoV-2-Research group (Mitja et al. Clin Infect Dis), 2020
                                     
                                    NCT04304053
                                    RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
                                    137/157 safety concern
                                    • statistically significant 25.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                                    • statistically significant 177.2-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                                    BCN PEP-CoV-2-Study 2 (Mitja Lancet), 2020
                                     
                                    NCT04304053
                                    RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
                                    142/165 inconclusive
                                      COMIHY, 2020
                                       
                                      NCT04340544
                                      RCThydroxychloroquinestandard of careCOVID 19 outpatientsNA
                                      -/- inconclusive
                                        COVID-PEP Severity (Skipper), 2020
                                         
                                        NCT04308668
                                        RCThydroxychloroquinecontrolCOVID 19 outpatientssome concern
                                        244/247 no results
                                          change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)
                                          COVID-PEP Severity (Skipper), 2020
                                           
                                          NCT04308668
                                          RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
                                          244/247 safety concern
                                          • statistically significant 1.8-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                                          change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)
                                          PATCH-cohort 1, 2020
                                           
                                          NCT04329923
                                          RCThydroxychloroquinecontrolCOVID 19 outpatientsNA
                                          -/- inconclusive
                                            Q-PROTECT -HCQ alone, 2020
                                             
                                            NCT04349592
                                            RCThydroxychloroquineplaceboCOVID 19 outpatientsNA
                                            152/152 inconclusive
                                            • inconclusive 5 % increase in PCR-negative conversion,PCR-negative conversion (7-day) (PE)

                                            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                                            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).